Chronic hepatitis C: How to recognize, when to treat

Consultant

Volumn 37, Issue 10, 1997, Pages 2596-2604

  Fallon, Harold J ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; RIBAVIRIN; TAUROURSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID; VIRUS RNA;

ALCOHOLISM; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; FATTY LIVER; FLU LIKE SYNDROME; HEMOCHROMATOSIS; HEMOLYSIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOTOXICITY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0031296056     PISSN: 00107069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 1995;22:1351-1354.
2. Sharara AL, Hunt CH, Hamilton JD. Hepatitis C. Ann Intern Med. 1996;125:658-668.
3. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 1995;332:1457-1462.
4. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-1055.